Artwork

Content provided by Life Sciences WA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Life Sciences WA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Biotech Investing on the ASX 101

23:37
 
Share
 

Manage episode 350248315 series 3427899
Content provided by Life Sciences WA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Life Sciences WA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of the Life Sciences WA Podcast, Dr Tara Speranza discusses her work as a healthcare and biotech analyst at Bell Potter Securities.

Dr Speranza is part of a group of three analysts who cover the healthcare and biotech sector in Australia, focusing on companies listed on the ASX. She has a background in molecular biology and endocrinology and has worked on various projects in the pharmaceutical industry.

Dr Speranza explains that as an analyst, she focuses on analysing the financial performance of healthcare and biotech companies, as well as their product pipelines and potential for growth. This involves looking at a wide range of factors, including a company's revenue and profit margins, its market share and competitors, and its ability to develop and commercialise new products and services.

Dr Speranza also discusses the unique challenges and opportunities in the healthcare industry. She notes that the industry is highly regulated, with strict rules governing the development and approval of new drugs and medical devices. This can make it difficult for companies to bring new products to market, but it also ensures that only safe and effective products are available to patients.

In addition, Dr Speranza emphasises the need to stay up-to-date on the latest scientific and technological developments in the field. She notes that the healthcare industry is constantly evolving, with new breakthroughs and innovations emerging all the time. As an analyst, she must be able to understand and interpret these developments in order to provide accurate and useful insights to her clients.

When it comes to investing in the life sciences industry in Western Australia, Dr Speranza believes that there are many exciting opportunities, particularly in the areas of biotechnology and medical technology. She encourages investors to do their due diligence and carefully evaluate the potential risks and rewards of different investments. She also emphasises the importance of building a diverse portfolio and being willing to take calculated risks in order to achieve success.

  continue reading

14 episodes

Artwork
iconShare
 
Manage episode 350248315 series 3427899
Content provided by Life Sciences WA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Life Sciences WA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of the Life Sciences WA Podcast, Dr Tara Speranza discusses her work as a healthcare and biotech analyst at Bell Potter Securities.

Dr Speranza is part of a group of three analysts who cover the healthcare and biotech sector in Australia, focusing on companies listed on the ASX. She has a background in molecular biology and endocrinology and has worked on various projects in the pharmaceutical industry.

Dr Speranza explains that as an analyst, she focuses on analysing the financial performance of healthcare and biotech companies, as well as their product pipelines and potential for growth. This involves looking at a wide range of factors, including a company's revenue and profit margins, its market share and competitors, and its ability to develop and commercialise new products and services.

Dr Speranza also discusses the unique challenges and opportunities in the healthcare industry. She notes that the industry is highly regulated, with strict rules governing the development and approval of new drugs and medical devices. This can make it difficult for companies to bring new products to market, but it also ensures that only safe and effective products are available to patients.

In addition, Dr Speranza emphasises the need to stay up-to-date on the latest scientific and technological developments in the field. She notes that the healthcare industry is constantly evolving, with new breakthroughs and innovations emerging all the time. As an analyst, she must be able to understand and interpret these developments in order to provide accurate and useful insights to her clients.

When it comes to investing in the life sciences industry in Western Australia, Dr Speranza believes that there are many exciting opportunities, particularly in the areas of biotechnology and medical technology. She encourages investors to do their due diligence and carefully evaluate the potential risks and rewards of different investments. She also emphasises the importance of building a diverse portfolio and being willing to take calculated risks in order to achieve success.

  continue reading

14 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide